Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by epitope selection
H. Akiba, J. Fujita, T. Ise, K. Nishiyama, T. Miyata, T. Kato, K. Namba, H. Ohno, H. Kamada, S. Nagata, K. Tsumoto
This study develops a biparatopic anti-TNFR2 antagonist that binds in a 1:1 ratio, preventing unwanted signal transduction and suppressing regulatory T cell proliferation.
bioRxiv · Dec 15, 2022Biochemistry